|1.||Jin, Hongnan: 7 articles (12/2008 - 03/2003)|
|2.||Wang, Ming: 7 articles (12/2008 - 03/2003)|
|3.||Young, Aiping H: 7 articles (12/2008 - 03/2003)|
|4.||Feng, Ningping: 7 articles (12/2008 - 03/2003)|
|5.||Wright, Jim A: 7 articles (12/2008 - 03/2003)|
|6.||Lee, Vivian: 5 articles (12/2008 - 11/2003)|
|7.||Lee, Yoon: 4 articles (12/2008 - 03/2005)|
|8.||Li, Hui: 4 articles (12/2008 - 03/2005)|
|9.||Du, Caigan: 4 articles (03/2005 - 03/2003)|
|10.||Gu, Xiaoping: 3 articles (12/2008 - 03/2005)|
04/01/2003 - "Direct comparisons with the anti-tumor activities of conventional drugs demonstrated that Virulizin has higher or equal efficacy against all four tumors tested. "
11/01/2003 - "Moreover, the anti-tumor efficacy of Virulizin observed in CD-1 nude mice was abrogated in mice that were depleted of macrophages, thus stimulation of macrophages may be one mechanism through which Virulizin acts. "
04/01/2003 - "Preclinical efficacy of Virulizin in human breast, ovarian and prostate tumor models."
03/01/2005 - "The aim of this study was to determine whether infiltration of natural killer (NK) cells into xenografted tumors is altered by Virulizin treatment, and whether such alterations contribute to the antitumor activity of Virulizin. "
04/01/2003 - "The purpose of this study was to define the anti-cancer activity of Virulizin against a number of solid human tumors. "
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
02/01/1994 - "Twenty-two patients were enrolled in a clinical trial to determine the toxicity and efficacy of the novel immunomodulator Virulizin in patients with measurable, biopsy-proven pancreatic cancer. "
01/01/2002 - "Lorus announced in June 2000 that it had completed a meta analysis of three phase I/II studies of virulizin that showed the drug increased survival and improved quality of life for pancreatic cancer patients. "
01/01/2002 - "The study aims to enrol 350 patients with advanced pancreatic cancer and will test the effectiveness of virulizin as first- and second-line treatment of pancreatic cancer. "
01/01/2002 - "The commencement of phase III clinical trials in Canada, for the treatment of pancreatic cancer, was delayed due to quality control problems with batches of virulizin and all clinical trials of virulizin were suspended as Lorus underwent a major restructuring programme. "
02/01/1994 - "Phase II trial of Virulizin in patients with pancreatic cancer."
|3.||Melanoma (Melanoma, Malignant)
11/01/2005 - "Cytotoxicity of NK cells isolated from Virulizin-treated mice was enhanced against NK-sensitive YAC-1 cells and C8161 human melanoma cells, but not against NK-insensitive P815 cells. "
01/01/2002 - "Lorus has entered into an exclusive 7-year distribution agreement with Faulding Canada Inc., giving Faulding (now part of Mayne Group) the right to market and sell virulizin in Mexico for the treatment of melanoma. "
01/01/2002 - "Virulizin is registered for the treatment of malignant melanoma in Mexico and is due to be launched there in 2002. "
04/01/2003 - "Virulizin is a novel biological response modifier (BRM) approved for the treatment of melanoma and is currently in a phase III clinical trial against advanced pancreatic cancer. "
03/01/2003 - "To define the anticancer efficacy of Virulizin in vivo as a single agent or in combination with conventional drugs in human pancreatic tumor and melanoma xenografts. "
|4.||Neoplasm Metastasis (Metastasis)
01/01/2002 - "Once growth reached 8 mm, tumors underwent marginal resection and the mice were assigned randomly to intraperitoneal (i.p.) cisplatin, Virulizin, a controlled release cisplatin-impregnated sponge (OPLA-Pt), a combination of treatments or no treatment and were evaluated for local regrowth, metastasis, and toxicity at 14 or 60 days after surgery. "
01/01/2002 - "The purpose of this study was to determine the efficacy of intracavitary cisplatin against local regrowth and metastasis after resection of a murine mammary carcinoma and the ability of a biologic response modifier (Virulizin) to enhance chemotherapy. "
|2.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|3.||Interleukin-17 (Interleukin 27)
|4.||Interleukin-12 (IL 12)
|6.||Messenger RNA (mRNA)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)